(UroToday.com) The TRACERx (TRAcking Cancer Evolution through therapy (Rx)) consortium aims to utilize cutting edge biologic techniques and analysis to uncover mechanisms of cancer evolution as well as explore intratumoral heterogeneity and its association with therapy response. In a 2018 paper, the consortium published genomic data from 1,206 primary tumor biopsies from 101 patients with clear cell renal cell carcinoma, highlighting substantial genetic diversity and complexity across and within tumors.1 In this presentation, Dr. Zhao reports analysis integrating spatial information with genomic data to further explore RCC evolution.